source
- Pfizer raises 2026 outlook as oncology and migraine growth balances Covid product declinePfizer announced it has increased its financial guidance for 2026, citing stronger performance in its cancer and migraine divisions. The company said sales of its Covid-19 related products have fa…
- Servier’s $1.5 billion muscular dystrophy drug sevasemten fails pivotal trialServier announced that its experimental muscular dystrophy therapy sevasemten did not meet its goals in a pivotal Phase III study. The trial, named GRAND CANYON, evaluated the drug’s ability to im…